The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia (Journal article)

Nakou, E. S./ Filippatos, T. D./ Kiortsis, D. N./ Derdemezis, C. S./ Tselepis, A. D./ Mikhailidis, D. P./ Elisaf, M. S.


Background: High-density lipoprotein (HDL) includes discrete subfractions. HDL exhibits anti-atherogenic properties, which have been partly linked to the activity of HDL-associated enzymes, such as the lipoprotein associated phospholipase A(2) (HDL-LpPLA(2)) and paraoxonase-1 (PON1). Objective: We assessed in an open-label randomised study the effect of orlistat and ezetimibe, alone or in combination, on plasma HDL subclasses and HDL-associated enzyme activities in overweight and obese subjects (body mass index > 28 kgm(2)) with hypercholesterolemia [total cholesterol > 200 mg/100 ml (5.2 mmol/l)]. Methods: Eighty-six people were prescribed a low-fat low-calorie diet and were randomly allocated to receive orlistat 120 mg, three times daily (O group), ezetimibe 10 mg/day (E group) or both (OE group) for 6 months. HDL subfractions were determined using a polyacrylamide gel-tube electrophoresis method. Results: Levels of HDL cholesterol (HDL-C) and apolipoprotein Al did not change significantly in any group. In group O the cholesterol concentration of HDL-2 subclass increased significantly, while the cholesterol of HDL-3 subclass decreased significantly. In groups E and OE HDL-2 subclass did not significantly change, while the cholesterol concentration of HDL-3 subclass decreased significantly. We observed a non-significant decrease in the HDL-LpPLA(2) and POW activity in all groups. However, the ratios of both enzyme activities to low-density lipoprotein cholesterol (LDL-C) levels (an index of atherogenicity) significantly increased in all groups. Conclusion: Although HDL-C levels did not change after treatment with orlistat and ezetimibe, alone or in combination, there were alterations of the HDL-2 and HDL-3 subclasses. The activity of HDL-LpPLA(2) and POW per mg LDL-C increased significantly in all groups.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας
Keywords: cholesterol,ezetimibe,high-density lipoprotein,lipoprotein associated phospholipase a(2),orlistat,paraoxonase,subclasses,triglycerides,activating-factor-acetylhydrolase,cardiovascular risk-factors,coronary-heart-disease,intervention trial,phospholipase a(2),metabolic syndrome,cholesterol,subfractions,paraoxonase,ldl
URI: http://olympias.lib.uoi.gr/jspui/handle/123456789/9617
ISSN: 1465-6566
Link: <Go to ISI>://000262018400003
http://informahealthcare.com/doi/abs/10.1517/14656560802548430
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.



 Please use this identifier to cite or link to this item:
http://olympias.lib.uoi.gr/jspui/handle/123456789/9617
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.